| editorial | Q871232 |
| scholarly article | Q13442814 |
| P2093 | author name string | Konstantinos Tziomalos | |
| Asterios Karagiannis | |||
| Vasilios G Athyros | |||
| Niki Katsiki | |||
| P2860 | cites work | Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure | Q33196686 |
| Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative | Q33728260 | ||
| MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial | Q33966645 | ||
| Efficacy and safety of benazepril for advanced chronic renal insufficiency | Q33992851 | ||
| Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis | Q34182804 | ||
| ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). | Q34196167 | ||
| Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes | Q57396250 | ||
| Cardiovascular disease in patients with renal disease: the role of statins | Q57750490 | ||
| Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial) | Q68231231 | ||
| Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group | Q69167761 | ||
| Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study | Q73106702 | ||
| Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality | Q73892882 | ||
| Statins and renal function. Is the compound and dose making a difference? | Q79665672 | ||
| Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Ev | Q80335956 | ||
| Response to 'Mildly decreased glomerular filtration rate is associated with poor coronary heart disease outcome' | Q83288563 | ||
| Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent? | Q83314735 | ||
| 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Deve | Q83631957 | ||
| Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study | Q84468684 | ||
| The role of statins in chronic kidney disease | Q84596811 | ||
| Therapeutic options for the management of the cardiorenal syndrome | Q34442587 | ||
| The cardiorenal syndrome: a review | Q34495307 | ||
| Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure | Q34620874 | ||
| Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. | Q35019423 | ||
| The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. | Q35587723 | ||
| Clinical features of cardio-renal syndrome in a cohort of consecutive patients admitted to an internal medicine ward | Q35622822 | ||
| Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study | Q35674320 | ||
| The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment. | Q36059341 | ||
| Addressing the challenges of cardiorenal syndrome | Q36481816 | ||
| Statins for improving renal outcomes: a meta-analysis | Q36500899 | ||
| Inflammation: a pivotal link between autoimmune diseases and atherosclerosis | Q36510624 | ||
| Beta blockers in the management of chronic kidney disease | Q36614867 | ||
| Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients | Q36944127 | ||
| Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure? | Q37138777 | ||
| Do we need to consider inflammatory markers when we treat atherosclerotic disease? | Q37141558 | ||
| Pleiotropic effects of statins--clinical evidence | Q37387536 | ||
| Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy | Q37704388 | ||
| Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference | Q37726571 | ||
| Pharmacological management of cardiorenal syndromes | Q39740830 | ||
| Statins and renal function in patients with diabetes mellitus | Q44648283 | ||
| The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease | Q44740390 | ||
| Relationship between heart failure treatment and development of worsening renal function among hospitalized patients | Q44754188 | ||
| Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease | Q44960569 | ||
| Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study | Q45389074 | ||
| Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). | Q45961602 | ||
| Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study | Q46489522 | ||
| Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease | Q46584977 | ||
| Long-term prognosis of acute kidney injury after acute myocardial infarction | Q46599330 | ||
| Cardiogenic shock secondary to combination of diltiazem and sotalol | Q46741032 | ||
| Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study | Q46945399 | ||
| Statins and heart failure | Q48243664 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 226-230 | |
| P577 | publication date | 2011-12-02 | |
| P1433 | published in | Open Cardiovascular Medicine Journal | Q15817299 |
| P1476 | title | Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role? | |
| P478 | volume | 5 |
| Q88241232 | Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018 |
| Q36310496 | Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl esters |
| Q38513740 | Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? |
Search more.